Pfizer, based in New York, struck the largest off-label promotion settlement to date in September 2009, agreeing to pay $2.3 billion for unauthorized marketing of its recalled painkiller Bextra and three other drugs. Pfizer acquired Bextra when it purchased Pharmacia Corp. in 2003. The settlement only involved sales practices and not the safety of the drug.